Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Replimune Group, Inc. (NASDAQ:REPL) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $12.00.

Several analysts recently commented on REPL shares. Leerink Partners upgraded shares of Replimune Group from a “market perform” rating to an “outperform” rating and raised their price target for the company from $11.00 to $17.00 in a research report on Tuesday, August 4th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research report on Tuesday, June 30th. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research report on Wednesday, August 12th.

Insider Transactions at Replimune Group

In other news, CFO Emily Luisa Hill sold 11,448 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,480.56. Following the transaction, the chief financial officer directly owned 225,108 shares of the company’s stock, valued at approximately $2,919,650.76. This trade represents a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the transaction, the insider owned 180,962 shares in the company, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 91,124 shares of company stock valued at $1,149,244. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Replimune Group in the 2nd quarter valued at approximately $99,171,000. RTW Investments LP increased its position in shares of Replimune Group by 11.6% during the 4th quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock worth $69,404,000 after purchasing an additional 744,620 shares during the last quarter. Montanova Capital LLC boosted its stake in Replimune Group by 4.0% during the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after buying an additional 168,000 shares during the period. State Street Corp lifted its stake in Replimune Group by 26.3% during the 4th quarter. State Street Corp now owns 3,693,107 shares of the company’s stock worth $35,897,000 after acquiring an additional 768,982 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Replimune Group by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock valued at $14,579,000 after acquiring an additional 9,707 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Down 0.6%

Shares of Replimune Group stock opened at $15.50 on Monday. The firm has a fifty day moving average price of $11.84 and a 200 day moving average price of $8.34. The stock has a market cap of $1.45 billion, a PE ratio of -4.92 and a beta of 0.88. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. Replimune Group has a 1 year low of $1.50 and a 1 year high of $16.15.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Equities research analysts predict that Replimune Group will post -2.94 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.